This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
A.C. Abrahams, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT01232257
First received: November 1, 2010
Last updated: October 25, 2012
Last verified: October 2012
  Purpose
Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.

Condition Intervention Phase
Chronic Kidney Disease Chronic Kidney Failure End Stage Kidney Disease End Stage Renal Disease Drug: N-acetylcysteine Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by A.C. Abrahams, UMC Utrecht:

Primary Outcome Measures:
  • Hydrogen sulfide (H2S) [ Time Frame: After 48 hours ]
    Investigate the effect of N-acetylcysteine on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients


Enrollment: 28
Study Start Date: July 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Healthy volunteers Drug: N-acetylcysteine
4 gifts of N-acetylcysteine 600 mg BID
Experimental: CKD patients
Patients with CKD stage 3-4 (GFR 15-60 ml/min)
Drug: N-acetylcysteine
4 gifts of N-acetylcysteine 600 mg BID
Experimental: Hemodialysis patients Drug: N-acetylcysteine
4 gifts of N-acetylcysteine 600 mg BID
Experimental: Peritoneal dialysis patients Drug: N-acetylcysteine
4 gifts of N-acetylcysteine 600 mg BID

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

Healthy volunteers:

  • Adult (> 18 years and older)
  • Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick
  • No medication use

CKD patient:

  • Adult (> 18 years and older)
  • CKD stage 3-4 (GFR 15-60 ml/min)

Hemodialysis patient:

  • Adult (> 18 years and older)
  • Hemodialysis patient

Peritoneal dialysis patient:

  • Adult (> 18 years and older)
  • Peritoneal dialysis patient

Exclusion criteria:

  • Unable to give informed consent
  • Hypersensitivity to N-acetylcysteine
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01232257

Locations
Netherlands
UMC Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
A.C. Abrahams
Investigators
Principal Investigator: M C Verhaar, MD, PhD UMC Utrecht
Principal Investigator: A C Abrahams, MD UMC Utrecht
  More Information

Responsible Party: A.C. Abrahams, MD, UMC Utrecht
ClinicalTrials.gov Identifier: NCT01232257     History of Changes
Other Study ID Numbers: H2S-NAC
Study First Received: November 1, 2010
Last Updated: October 25, 2012

Keywords provided by A.C. Abrahams, UMC Utrecht:
Chronic kidney disease
Chronic kidney failure
End stage kidney disease
End stage renal disease
Hydrogen sulfide
N-acetylcysteine
Acetylcysteine

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Renal Insufficiency
Urologic Diseases
Acetylcysteine
N-monoacetylcystine
Hydrogen Sulfide
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes
Gasotransmitters
Neurotransmitter Agents

ClinicalTrials.gov processed this record on September 19, 2017